Trial Profile
A Double-Blind, Randomized, Crossover Design Study To Compare The Rocuronium Reversal By Sugammadex To Succinylcholine For Electroconvulsive Therapy (ECT)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Sugammadex (Primary) ; Rocuronium bromide; Suxamethonium chloride
- Indications Neuromuscular blockade
- Focus Therapeutic Use
- Acronyms CRoSSECT
- 26 Oct 2022 Primary endpoint has been met, (Recovery time of T1 to 90% baseline); as per Results presented at the ANESTHESIOLOGY 2022 Annual Meeting of the American Society of Anesthesiologists
- 26 Oct 2022 Status has been changed to completed, as per Results presented at the ANESTHESIOLOGY 2022 Annual Meeting of the American Society of Anesthesiologists
- 26 Oct 2022 Results presented at the ANESTHESIOLOGY 2022 Annual Meeting of the American Society of Anesthesiologists